A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
• Age ≥50 and ≤85 on the date of signing the informed consent, males or females;
• BMI≥18kg/m2 and ≤32 kg/m2, weight ≥45 kg且≤100 kg at screening or baseline；
• must meet the diagnostic criteria for MCI due to AD or mild AD;
• The total score of HAMD-17 should be ≤10 scores at screening;
• The score of Hachinski ischemic scale should be ≤4 scores at screening;
• amyloid PET scan results from the central laboratory confirmed the presence of pathological changes in AD;
• Agreed to test ApoE genotype;
• Have a stable caregiver; where symptomatic drugs for AD is used, they must be stable for at least 1 months prior to the screening visit;